Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) has earned a consensus recommendation of “Moderate Buy” from the nine research firms that are presently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $34.8333.

A number of research firms have recently weighed in on GLUE. Jefferies Financial Group reiterated a “buy” rating on shares of Monte Rosa Therapeutics in a research note on Monday. Guggenheim upped their price target on shares of Monte Rosa Therapeutics from $30.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. JPMorgan Chase & Co. increased their price target on Monte Rosa Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Weiss Ratings upgraded Monte Rosa Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday. Finally, Zacks Research cut Monte Rosa Therapeutics from a “hold” rating to a “strong sell” rating in a report on Monday, July 6th.

Monte Rosa Therapeutics Stock Down 2.4%

Shares of NASDAQ:GLUE opened at $21.52 on Thursday. Monte Rosa Therapeutics has a 52-week low of $4.12 and a 52-week high of $25.77. The stock has a market cap of $1.82 billion, a price-to-earnings ratio of -14.54 and a beta of 1.56. The business has a 50-day moving average price of $20.85 and a 200-day moving average price of $19.66.

Monte Rosa Therapeutics (NASDAQ:GLUE) last issued its earnings results on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). Monte Rosa Therapeutics had a negative net margin of 302.69% and a negative return on equity of 40.99%. The firm had revenue of $4.21 million during the quarter, compared to analysts’ expectations of $10.95 million. As a group, equities analysts anticipate that Monte Rosa Therapeutics will post -1.23 EPS for the current fiscal year.

Insider Buying and Selling

In other Monte Rosa Therapeutics news, Director Anthony M. Manning sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $23.11, for a total value of $231,100.00. Following the sale, the director owned 10,000 shares in the company, valued at approximately $231,100. This represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Sharon Townson sold 6,000 shares of the firm’s stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $23.31, for a total transaction of $139,860.00. Following the sale, the insider directly owned 67,845 shares in the company, valued at $1,581,466.95. The trade was a 8.13% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 81,778 shares of company stock valued at $1,768,581 in the last ninety days. Insiders own 6.40% of the company’s stock.

Institutional Trading of Monte Rosa Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC purchased a new position in Monte Rosa Therapeutics in the 1st quarter valued at about $1,065,000. Goldman Sachs Group Inc. grew its stake in Monte Rosa Therapeutics by 122.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 356,112 shares of the company’s stock valued at $1,652,000 after acquiring an additional 196,238 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in Monte Rosa Therapeutics in the 1st quarter valued at about $76,000. Geode Capital Management LLC raised its holdings in Monte Rosa Therapeutics by 12.0% in the 2nd quarter. Geode Capital Management LLC now owns 1,124,160 shares of the company’s stock valued at $5,071,000 after acquiring an additional 120,098 shares during the last quarter. Finally, American Century Companies Inc. lifted its stake in Monte Rosa Therapeutics by 301.4% in the 2nd quarter. American Century Companies Inc. now owns 403,045 shares of the company’s stock worth $1,818,000 after purchasing an additional 302,639 shares in the last quarter. 79.96% of the stock is owned by hedge funds and other institutional investors.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.